DSpace Repository

Molecular Docking Studies and Synthesis of Amino-oxy-diarylquinoline Derivatives as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors

Show simple item record

dc.contributor.author Makarasen A.
dc.contributor.author Kuno M.
dc.contributor.author Patnin S.
dc.contributor.author Reukngam N.
dc.contributor.author Khlaychan P.
dc.contributor.author Deeyohe S.
dc.contributor.author Intachote P.
dc.contributor.author Saimanee B.
dc.contributor.author Sengsai S.
dc.contributor.author Boonsri P.
dc.contributor.author Chaivisuthangkura A.
dc.contributor.author Sirithana W.
dc.contributor.author Techasakul S.
dc.contributor.author Dr.
dc.date.accessioned 2021-04-05T03:04:46Z
dc.date.available 2021-04-05T03:04:46Z
dc.date.issued 2019
dc.identifier.issn 21949379
dc.identifier.other 2-s2.0-85075814506
dc.identifier.uri https://ir.swu.ac.th/jspui/handle/123456789/12655
dc.identifier.uri https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075814506&doi=10.1055%2fa-0968-1150&partnerID=40&md5=ff3b3822d05ec10d157aa7796904d722
dc.description.abstract In this study, amino-oxy-diarylquinolines were designed using structure-guided molecular hybridization strategy and fusing of the pharmacophore templates of nevirapine (NVP), efavirenz (EFV), etravirine (ETV, TMC125) and rilpivirine (RPV, TMC278). The anti-HIV-1 reverse transcriptase (RT) activity was evaluated using standard ELISA method, and the cytotoxic activity was performed using MTT and XTT assays. The primary bioassay results indicated that 2-amino-4-oxy-diarylquinolines possess moderate inhibitory properties against HIV-1 RT. Molecular docking results showed that 2-amino-4-oxy-diarylquinolines 8(a-d) interacted with the Lys101 and His235 residue though hydrogen bonding and interacted with Tyr318 residue though π-π stacking in HIV-1 RT. Furthermore, 8a and 8d were the most potent anti-HIV agents among the designed and synthesized compounds, and their inhibition rates were 34.0% and 39.7% at 1 μM concentration. Interestingly, 8a was highly cytotoxicity against MOLT-3 (acute lymphoblastic leukemia), with an IC 50 of 4.63±0.62 μg/mL, which was similar with that in EFV and TMC278 (IC 50 7.76±0.37 and 1.57±0.20 μg/ml, respectively). Therefore, these analogs of the synthesized compounds can serve as excellent bases for the development of new anti-HIV-1 agents in the near future. © 2019 Georg Thieme Verlag. All rights reserved.
dc.subject 4 (2',6' dimethyl 4' cyanophenoxy) 2 (4" cyanophenyl)aminoquinoline
dc.subject 4 (2',6' dimethyl 4' cyanophenoxy) 2 chloroquinoline
dc.subject 4 (2',6' dimethyl 4' cyanophenoxy) 6 (4'' cyanophenyl)aminoquinoline
dc.subject 4 (2',6' dimethyl 4' cyanophenoxy) 6 nitroquinoline
dc.subject 4 (2',6' dimethyl 4' formylphenoxy) 2 (4'' cyanophenyl)aminoquinoline
dc.subject 4 (2',6' dimethyl 4' formylphenoxy) 2 chloroquinoline
dc.subject 4 (2',6' dimethyl 4' formylphenoxy) 6 (4" cyanophenyl)aminoquinoline
dc.subject 4 (2',6' dimethyl 4' formylphenoxy) 6 nitroquinoline
dc.subject 4 (4' cyanophenoxy) 2 (4" cyanophenyl)aminoquinoline
dc.subject 4 (4' cyanophenoxy) 2 chloroquinoline
dc.subject 4 (4' cyanophenoxy) 6 (4'' cyanophenyl)aminoquinoline
dc.subject 4 (4' cyanophenoxy) 6 nitroquinoline
dc.subject 4 (4' formylphenoxy) 2 (4" cyanophenyl)aminoquinoline
dc.subject 4 (4' formylphenoxy) 2 chloroquinoline
dc.subject 4 (4' formylphenoxy) 6 (4'' cyanophenyl)aminoquinoline
dc.subject 4 (4' formylphenoxy) 6 nitroquinoline
dc.subject anti human immunodeficiency virus agent
dc.subject antileukemic agent
dc.subject doxorubicin
dc.subject efavirenz
dc.subject etoposide
dc.subject etravirine
dc.subject nevirapine
dc.subject nonnucleoside reverse transcriptase inhibitor
dc.subject quinoline derivative
dc.subject rilpivirine
dc.subject unclassified drug
dc.subject anti human immunodeficiency virus agent
dc.subject benzoxazine derivative
dc.subject efavirenz
dc.subject etravirine
dc.subject nevirapine
dc.subject pyridazine derivative
dc.subject quinoline derivative
dc.subject reverse transcriptase, Human immunodeficiency virus 1
dc.subject rilpivirine
dc.subject RNA directed DNA polymerase
dc.subject RNA directed DNA polymerase inhibitor
dc.subject antileukemic activity
dc.subject antiviral activity
dc.subject Article
dc.subject cell viability
dc.subject comparative study
dc.subject concentration response
dc.subject controlled study
dc.subject cytotoxicity
dc.subject drug conformation
dc.subject drug cytotoxicity
dc.subject drug design
dc.subject drug potency
dc.subject drug protein binding
dc.subject drug structure
dc.subject drug synthesis
dc.subject enzyme inhibition
dc.subject enzyme linked immunosorbent assay
dc.subject human
dc.subject human cell
dc.subject Human immunodeficiency virus 1
dc.subject hydrogen bond
dc.subject IC50
dc.subject molecular docking
dc.subject molecular hybridization
dc.subject MOLT-3 cell line
dc.subject MRC-5 cell line
dc.subject MTT assay
dc.subject pharmacophore
dc.subject structure activity relation
dc.subject XTT assay
dc.subject chemistry
dc.subject drug effect
dc.subject Human immunodeficiency virus 1
dc.subject Human immunodeficiency virus infection
dc.subject metabolism
dc.subject molecular docking
dc.subject tumor cell line
dc.subject Anti-HIV Agents
dc.subject Benzoxazines
dc.subject Cell Line, Tumor
dc.subject Diarylquinolines
dc.subject HIV Infections
dc.subject HIV Reverse Transcriptase
dc.subject HIV-1
dc.subject Humans
dc.subject Molecular Docking Simulation
dc.subject Nevirapine
dc.subject Pyridazines
dc.subject Reverse Transcriptase Inhibitors
dc.subject Rilpivirine
dc.title Molecular Docking Studies and Synthesis of Amino-oxy-diarylquinoline Derivatives as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors
dc.type Article
dc.rights.holder Scopus
dc.identifier.bibliograpycitation Drug Research. Vol 69, No.12 (2019), p.671-682
dc.identifier.doi 10.1055/a-0968-1150


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics